You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Sotagliflozin with insulin for treating type 1 diabetes

  • Technology appraisal guidance
  • Reference number: TA622
  • Published:  12 February 2020
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 143 KB)

    Published:
    12 February 2020

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 290 KB)

    Published:
    22 November 2019
  • Committee papers (PDF 9.83 MB)

    Published:
    22 November 2019

Invitation to participate

  • Final scope (PDF 246 KB)

    Published:
    12 February 2020
  • Final stakeholder list (PDF 248 KB)

    Published:
    12 February 2020
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 514 KB)

    Published:
    12 February 2020
  • Equality impact assessment (Scoping) (PDF 127 KB)

    Published:
    12 February 2020
Back to top